About Max
This author has not written his bio yet.
But we are proud to say that Max contributed 567 entries already.
Entries by Max
Newsletter 39/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! A quick note from me: our newsletter runs on Kit.com, which costs $290/year to keep going. If you enjoy these updates and would like to chip in to help cover the renewal, you can do so here, or send me a […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 6/2026 February 8, 2026
- SPR1020: a Promising PARP1-Selective Inhibitor in Advanced Solid Tumors (Including mCRPC) February 6, 2026
- Dual-Action Nanomaterial Eradicates Cancer Cells And Spares Healthy Tissue February 6, 2026
- Phase 1 Trial GTB-5550, a Immunotherapy Targeting B7-H3 in Solid Tumors (Including mCRPC) February 6, 2026
